$0.8387
0.01171.41%
At close: Nov 13, 4:00 PM EST
$0.8349
-0.0038-0.45%
After Hours: 7:55 PM EST
Allogene Therapeutics Inc
ALLONASDAQ
Allogene Therapeutics fell 31.8% from $1.23 to $0.84, behind the S&P 500's +12.3%. Its worst day was Apr 14 (−25.5%), and its low came Nov 12 at $0.83.
Nov 14, 2025 – Nov 13, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
Citizens moved Allogene Therapeutics from Market Perform to Market Outperform with a $5.00 price target; shares rose 14.8%.
+14.8% · S&P 500 +0.7%
Allogene Therapeutics shares rose 15.7%, while the S&P 500 fell 0.3%.
Story events cover the past 12 months · Times ET
+15.7% · S&P 500 −0.3%
Allogene Therapeutics shares rose 20.0%, while the S&P 500 rose 0.2%.
+20.0%, the year's best day · S&P 500 +0.2%
EPS of $-0.17 beat the $-0.23 estimate on $0.00 revenue (est. $2,000.00).
−2.8% · S&P 500 −0.6%
Allogene Therapeutics shares rose 17.9%, while the S&P 500 rose 1.1%.
+17.9% · S&P 500 +1.1%
Allogene Therapeutics closed at its highest level of the year, 148.8% above where the year started.
+12.5%, on 88M shares, the year's heaviest volume · S&P 500 +1.0%
EPS of $-0.18 beat the $-0.18 estimate on $0.00 revenue (est. $1,820.00).
−8.2% · S&P 500 +0.8%
EPS of $-0.13 beat the $-0.15 estimate on $4.6M revenue (est. $2,220.00).
−4.3% · S&P 500 +0.7%
EPS of $-0.15 missed the $-0.14 estimate on $0.00 revenue (est. $2,220.00).
−4.6% · S&P 500 +0.3%
Where it ended: a close of $0.84 on Nov 13, 2026. Up next: Q4 2026 earnings on Mar 11, 2027 (EPS est. $-0.15, revenue est. $2,220.00).
Nothing in the past 12 months.
All ALLO dividend historyReplay the year: the line draws itself and stops at each of the 9 moments with what happened and how the stock reacted.
Chart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for ALLO and SPY from Benzinga historical bars. Not investment advice.
